The Exchange had sought clarification from Venus Remedies Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is enclosed.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE asked Venus Remedies to explain why the Limited Review Report submitted for the quarter ended September 2025 was not in the format prescribed by SEBI under Regulation 33 of the Listing Obligations rules. The company has submitted its response to the exchange. The issue is procedural in nature, related to document formatting rather than the underlying financial figures or audit findings. No financial restatement or audit qualification has been mentioned.
This is a minor compliance formality and unlikely to affect the stock price or shareholder value. Investors should wait to see if SEBI accepts the company's explanation, but there is no indication of any penalty or deeper regulatory concern.